Please login to the form below
Strides Arcolab
This page shows the latest Strides Arcolab news and features for those working in and with pharma, biotech and healthcare.
India turns down patent on Gilead's Sovaldi
Cipla, Cadila Healthcare, Hetero, Strides Arcolab, Ranbaxy, Sequent Scientific and Mylan) at a 7% royalty rate.
Latest news
-
Sovaldi deal for developing world ‘falls short’
Strides Arcolab - include some of the world's largest generic players, reports the Pharmalot blog.
-
Pfizer inks $360m deal to buy InnoPharma
Last year, generics giant Mylan made a big leap forward in the sector with a $1.6bn agreement to buy Strides Arcolab's sterile injectables unit Agila, while Becton Dickinson has
-
Hikma to retain injectables unit
Hikma said in March it decided to look into the future of the division after being sent unsolicited offers in the wake of Mylan's $1.6bn deal to acquire Strides ... Arcolab's injectables unit.
-
Injectables land-grab set to continue as Hikma reports offers
Hikma has said it is looking into the future of its injectable drugs unit after overtures from possible buyers, just days after Mylan agreed a $1.6bn deal to buy Strides ... Mylan said when it announced its deal for Strides Arcolab's Agila unit that it
-
Mylan agrees $1.6bn deal to buy Agila injectables unit
Generics firm becomes “top three player” in injectables. Consolidation continues apace in the generics sector, with Mylan agreeing a $1.6bn deal to acquire Strides Arcolab of India's sterile injectables
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Pharma deals in May 2015
360. Aspen/ Strides Arcolab. Divestment. Range of branded and generic drugs.
-
Deal Watch table for September 2014
200. Shasun / Strides Arcolab. Company acquisition. Shasun is an Indian API and generic company.
-
Pharma deals during September 2014
year. In India this month, Strides Arcolab has acquired another Indian generic and API supplier Shasun in an all stock deal worth $200m to add products to its portfolio.
-
The rise of chronic disease in BRIC markets
with Strides Arcolab to jointly manufacture and distribute generic cancer drugs in developing markets.
-
Pharma deals during February 2013
Geographic expansion and consolidation. Mylan, the generics giant, has announced a trio of deals with Indian companies this month. In the largest, it announced its planned acquisition of Strides Arcolab's
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Featured jobs
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
-
Senior Medical Writer
-
Salary TBC
- Scientific Director – Medical Communications
-
Salary TBC
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
- Senior Account Manager, Medical Communications, London
-
Excellent package
-
Account Director, Medical Education
-
Salary TBC
- Freelance Senior Account Manager / Account Director - Healthcare...
-
£350-400 depending on experience
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Health Consultant - Brand Comms
-
Competitive Salary
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Digital Account Director
-
Salary TBC
- Freelance AM/ AD Healthcare Advertising
-
£350-400 depending on experience
Subscribe to our email news alerts
- Keytruda adds another NSCLC approval in Europe
- Roche gets FDA nod for Tecentriq in small cell lung cancer
- Genomics integration: can the NHS rise to the challenge?
- Blood disorder specialists Imara raises $63m
- NICE wants to stop saying ‘no’ – but needs pharma’s co-operation
- Three questions that should anchor your brand strategy
PMHub
Cello Health
Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...
Latest intelligence
- Genomics integration: can the NHS rise to the challenge?
- Experts gather to discuss the UK’s genomic landscape...
- “Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
- The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
- The Future of Pharma sales: fast forward to 2029
- Change is inevitable, and necessary, for growth in business....
Quick links
Infographics
